CA2802176A1 - Methods of mitigating effects of radiation and reducing the risk of systemic infection - Google Patents

Methods of mitigating effects of radiation and reducing the risk of systemic infection Download PDF

Info

Publication number
CA2802176A1
CA2802176A1 CA2802176A CA2802176A CA2802176A1 CA 2802176 A1 CA2802176 A1 CA 2802176A1 CA 2802176 A CA2802176 A CA 2802176A CA 2802176 A CA2802176 A CA 2802176A CA 2802176 A1 CA2802176 A1 CA 2802176A1
Authority
CA
Canada
Prior art keywords
gly
asp
ala
subject
thrombin peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2802176A
Other languages
English (en)
French (fr)
Inventor
Darrell Carney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CA2802176A1 publication Critical patent/CA2802176A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
CA2802176A 2010-06-11 2011-06-10 Methods of mitigating effects of radiation and reducing the risk of systemic infection Abandoned CA2802176A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35406710P 2010-06-11 2010-06-11
US61/354,067 2010-06-11
PCT/US2011/040006 WO2011156729A2 (en) 2010-06-11 2011-06-10 Methods of mitigating effects of radiation and reducing the risk of systemic infection

Publications (1)

Publication Number Publication Date
CA2802176A1 true CA2802176A1 (en) 2011-12-15

Family

ID=44533067

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2802176A Abandoned CA2802176A1 (en) 2010-06-11 2011-06-10 Methods of mitigating effects of radiation and reducing the risk of systemic infection

Country Status (5)

Country Link
EP (1) EP2579891A2 (https=)
JP (1) JP2013529600A (https=)
AU (1) AU2011265228A1 (https=)
CA (1) CA2802176A1 (https=)
WO (1) WO2011156729A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021207411A1 (en) * 2020-04-07 2021-10-14 Chrysalis Biotherapeutics Tp508 acute therapy for patients with respiratory virus infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352664A (en) * 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
EP1539214A4 (en) 2002-07-02 2008-01-02 Orthologic Corp Thrombin
AU2003247848B2 (en) 2002-07-02 2006-12-21 The Board Of Regents, The University Of Texas System Thrombin peptide derivative dimers
US7294596B2 (en) 2005-03-14 2007-11-13 Diamorph Ceramic Ab Sintered ceramic material with improved properties and method for its manufacturing
CN101563102B (zh) * 2006-09-22 2014-12-17 德克萨斯系统大学董事会 治疗内皮功能障碍的方法
EP2155234A1 (en) * 2007-04-10 2010-02-24 The Board of Regents,The University of Texas System Combination therapy for chronic dermal ulcers

Also Published As

Publication number Publication date
EP2579891A2 (en) 2013-04-17
AU2011265228A1 (en) 2013-05-23
JP2013529600A (ja) 2013-07-22
WO2011156729A3 (en) 2012-05-10
WO2011156729A2 (en) 2011-12-15

Similar Documents

Publication Publication Date Title
EP2875826B1 (en) Composition for preventing or treating sepsis
RU2139085C1 (ru) Средство, стимулирующее репаративные процессы, и способ его применения
ES2741476T3 (es) Método para el tratamiento o reducción de PFE
JP4307561B2 (ja) 創傷の治癒
EP3539557B1 (en) Bifunctional peptide having capability to reduce inflammation and capability to facilitate differentiation of stem cells into chondrocytes and use thereof
CN102482323B (zh) 新型肽及其应用
ZA200603396B (en) Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
AU7439801A (en) Use of acrp30 globular head to promote increases in muscle mass and muscle differentiation
US20130101574A1 (en) Methods of using thrombin peptide derivatives
CA2802176A1 (en) Methods of mitigating effects of radiation and reducing the risk of systemic infection
US8133491B1 (en) Compositions and methods for treatment of hyperplastic disorders
EP2687224A1 (en) Medicament for wound treatment
TW201302214A (zh) 治療或預防皮膚癌之類鋅手指胜肽、其表現質體、及包含其之醫藥組成物
SG11202110469PA (en) Ghrh or analogues thereof for use in treatment of hepatic disease
Berlanga Heberprot-P: antecedentes experimentales y bases farmacológicas
WO2024189056A1 (en) Annexin a1 administration regime
JP2025517354A (ja) 自己免疫疾患を治療する方法
US8895502B2 (en) β2-glycoprotein I peptide inhibitors
US10646553B2 (en) Use of recombinant human calcineurin B subunit
CN101657465A (zh) 肽、组合物及其应用
WO2003045322A2 (en) Method for treating and preventing pancreatitis
RU2008125169A (ru) Терапевтическое средство для ускоренного заживления кожи, содержащее в качестве активного ингредиента грелин и его производные или вещество, воздействующее на рецептор ghs-r1а
US10028906B2 (en) Method and kit for treating a solid tumor and associated desmoplasia
RU2833679C1 (ru) Применение пептида Thr-Lys-Pro-Arg-Pro-Gly-Pro для защиты инсулярного аппарата поджелудочной железы и её экзокринного отдела от токсических деструктивных воздействий
RU2794024C1 (ru) Набор лекарственных препаратов для проведения курсовой третичной профилактики онкологических заболеваний для иммуномодулирующего воздействия при комбинированной терапии и способ третичной профилактики онкологических заболеваний с использованием комбинированной терапии с помощью набора лекарственных препаратов для иммуномодулирующего воздействия

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20160610